Works matching AU YOUNES, ANAS

Results: 141
    1
    2

    Localized Nodal Indolent Lymphoma.

    Published in:
    Oncology (08909091), 2013, v. 27, n. 8, p. 786
    By:
    • HOPPE, BRADFORD S.;
    • HODGSON, DAVID C.;
    • ADVANI, RANJANA;
    • DABAJA, BOUTHAINA S.;
    • FLOWERS, CHRISTOPHER R.;
    • HA, CHUL S.;
    • METZGER, MONIKA L.;
    • PLASTARAS, JOHN P.;
    • ROBERTS, KENNETH B.;
    • SHAPIRO, RONALD;
    • TEREZAKIS, STEPHANIE A.;
    • WINKFIELD, KAREN M.;
    • YOUNES, ANAS;
    • CONSTINE, LOUIS S.
    Publication type:
    Article
    3
    4
    5

    ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.

    Published in:
    Oncology (08909091), 2016, v. 30, n. 12, p. 1099
    By:
    • Winkfield, Karen M.;
    • Advani, Ranjana H.;
    • Ballas, Leslie K.;
    • Dabaja, Bouthaina S.;
    • Dhakal, Sughosh;
    • Flowers, Christopher R.;
    • Ha, Chul Soo;
    • Hoppe, Bradford S.;
    • Mansur, David B.;
    • Mendenhall, Nancy P.;
    • Metzger, Monika L.;
    • Plastaras, John P.;
    • Roberts, Kenneth B.;
    • Shapiro, Ronald;
    • Smith, Sonali M.;
    • Terezakis, Stephanie A.;
    • Younes, Anas;
    • Constine, Louis S.
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

    Published in:
    2018
    By:
    • Romaguera, Jorge E.;
    • Wang, Michael;
    • Feng, Lei;
    • Fayad, Luis E.;
    • Hagemeister, Frederick;
    • McLaughlin, Peter;
    • Rodriguez, M. Alma;
    • Fanale, Michelle;
    • Orlowski, Robert;
    • Kwak, Larry W.;
    • Neelapu, Sattva;
    • Oki, Yasuhiro;
    • Pro, Barbara;
    • Younes, Anas;
    • Samaniego, Felipe;
    • Fowler, Nathan;
    • Hartig, Kimberly;
    • Valentinetti, Marisa;
    • Smith, Judy;
    • Ford, Peggy
    Publication type:
    journal article
    24
    25

    A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.

    Published in:
    EJHaem, 2023, v. 4, n. 4, p. 1042, doi. 10.1002/jha2.796
    By:
    • Kostakoglu, Lale;
    • Martelli, Maurizio;
    • Sehn, Laurie H.;
    • Davies, Andrew;
    • Trněný, Marek;
    • Herold, Michael;
    • Vitolo, Umberto;
    • Hiddemann, Wolfgang;
    • Trotman, Judith;
    • Knapp, Andrea;
    • Mattiello, Federico;
    • Nielsen, Tina G.;
    • Sahin, Deniz;
    • Sellam, Gila;
    • Ward, Carol;
    • Younes, Anas
    Publication type:
    Article
    26

    Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

    Published in:
    2017
    By:
    • Diefenbach, Catherine S.;
    • Connors, Joseph M.;
    • Friedberg, Jonathan W.;
    • Leonard, John P.;
    • Kahl, Brad S.;
    • Little, Richard F.;
    • Baizer, Lawrence;
    • Evens, Andrew M.;
    • Hoppe, Richard T.;
    • Kelly, Kara M.;
    • Persky, Daniel O.;
    • Younes, Anas;
    • Kostakaglu, Lale;
    • Bartlett, Nancy L.
    Publication type:
    journal article
    27
    28
    29

    Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

    Published in:
    2015
    By:
    • Oki, Yasuhiro;
    • Ewer, Michael S;
    • Lenihan, Daniel J;
    • Fisch, Michael J;
    • Hagemeister, Fredrick B;
    • Fanale, Michelle;
    • Romaguera, Jorge;
    • Pro, Barbara;
    • Fowler, Nathan;
    • Younes, Anas;
    • Astrow, Alan B;
    • Huang, Xuelin;
    • Kwak, Larry W;
    • Samaniego, Felipe;
    • McLaughlin, Peter;
    • Neelapu, Sattva S;
    • Wang, Michael;
    • Fayad, Luis E;
    • Durand, Jean-Bernard;
    • Alma Rodriguez, M
    Publication type:
    journal article
    30
    31
    32
    33

    Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphomaPresented in part at the 39th annual meeting of the American Society of Clinical Oncology, May 31, 2003‐June 3, 2003, Chicago, Illinois.

    Published in:
    Cancer (0008543X), 2007, v. 109, n. 1, p. 77, doi. 10.1002/cncr.22389
    By:
    • Yasuhiro Oki;
    • Peter McLaughlin;
    • Luis E. Fayad;
    • Barbara Pro;
    • Paul F. Mansfield;
    • Gary L. Clayman;
    • L. Jeffrey Medeiros;
    • Larry W. Kwak;
    • Pramod K. Srivastava;
    • Anas Younes
    Publication type:
    Article
    34
    35
    36
    37

    Thalidomide for patients with recurrent lymphoma.

    Published in:
    Cancer (0008543X), 2004, v. 100, n. 6, p. 1186
    By:
    • Barbara Pro;
    • Anas Younes;
    • Maher Albitar;
    • Nam H. Dang;
    • Felipe Samaniego;
    • Jorge Romaguera;
    • Peter McLaughlin;
    • Fredrick B. Hagemeister;
    • Maria A. Rodriguez;
    • Marilyn Clemons;
    • Fernando Cabanillas
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46

    Brentuximab vedotin.

    Published in:
    Nature Reviews Drug Discovery, 2012, v. 11, n. 1, p. 19, doi. 10.1038/nrd3629
    By:
    • Younes, Anas;
    • Yasothan, Uma;
    • Kirkpatrick, Peter
    Publication type:
    Article
    47
    48
    49

    FDG PET/CT imaging as a biomarker in lymphoma.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2015, v. 42, n. 4, p. 623, doi. 10.1007/s00259-014-2973-6
    By:
    • Meignan, Michel;
    • Itti, Emmanuel;
    • Gallamini, Andrea;
    • Younes, Anas
    Publication type:
    Article
    50